12 results on '"Josep Pardos Gea"'
Search Results
2. Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome
- Author
-
Ariadna Anunciación-Llunell, Cándido Muñoz, Dirk Roggenbuck, Stefano Frasca, Josep Pardos-Gea, Enrique Esteve-Valverde, Jaume Alijotas-Reig, and Francesc Miró-Mur
- Subjects
antiphospholipid antibodies ,thrombotic antiphospholipid syndrome ,obstetric antiphospholipid syndrome ,non-criteria antiphospholipid antibody ,line Immunoassay ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune condition characterised by the presence of antiphospholipid antibodies (aPL) associated with vascular thrombosis and/or pregnancy complications. In a cohort of 74 yet diagnosed APS individuals fulfilling Sydney laboratory criteria (twice positive for lupus anticoagulant, anticardiolipin, aCL, and/or anti-β2glycoprotein I, aβ2GPI), 33 out of 74 were obstetric APS (OAPS) and 41 thrombotic APS (TAPS) patients. 39% of TAPS patients were women. Although aPL detection was persistent, we observed an oscillatory aPL positivity in 56.7% and a transient seroconversion in 32.4% of APS patients at enrolment. Thus, we tested their sera in a line immunoassay that simultaneously detected IgG or IgM for criteria (aCL and aβ2GPI) and non-criteria (anti-phosphatidylserine, aPS; anti-phosphatidic acid, aPA; anti-phosphatidylinositol, aPI; anti-annexin 5, aA5; anti-prothrombin, aPT; anti-phosphatidylethanolamine; anti-phosphatidylglycerol, and anti-phosphatidylcholine) aPL. OAPS and TAPS patients displayed different but overlapping clusters based on their aPL reactivities. Specifically, while OAPS patients showed higher aPA, aPS, aA5, aβ2GPI and aPT IgM levels than TAPS patients, the latter displayed higher reactivity in aCL, aPI and aA5 IgG. Eventually, with a cut-off of the 99th percentile established from a population of 79 healthy donors, TAPS patients significantly tested more positive for aCL and aA5 IgG than OAPS patients, who tested more positive for aPA, aPS and aβ2GPI IgM. Transiently seronegative APS patients showed non-criteria aPL positivity twice in sera obtained 3 months apart. Overall, our data show that APS patients presented clusters of aPL that define different profiles between OAPS and TAPS, and persistent non-criteria aPL positivity was observed in those who are transiently seronegative.
- Published
- 2022
- Full Text
- View/download PDF
3. Corrigendum to 'Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group' [Placenta. 136 (2023 Apr 3) 29–34]
- Author
-
Enrique Esteve-Valverde, Jaume Alijotas-Reig, Cristina Belizna, Joana Marques-Soares, Ariadna Anunciacion-Llunell, Carlos Feijóo-Massó, Luis Sáez-Comet, Arsene Mekinian, Raquel Ferrer-Oliveras, Elmina Lefkou, Stephanie Morales-Pérez, Ariela Hoxha, Angela Tincani, Cecilia Nalli, Josep Pardos-Gea, Luca Marozio, Aldo Maina, Gerard Espinosa, Ricard Cervera, Sara De Carolis, Omar Latino, Sebastian Udry, Elisa Llurba, Carmen Garrido-Gimenez, Laura Trespidi, Maria Gerosa, Cecilia B. Chighizola, Patrizia Rovere-Querini, Valentina Canti, Karoline Mayer-Pickel, Sara Tabacco, Anna Arnau, and Francesc Miró-Mur
- Subjects
Reproductive Medicine ,Obstetrics and Gynecology ,Developmental Biology - Published
- 2023
4. Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review
- Author
-
Joana Rita Marques-Soares, Enrique Esteve-Valverde, Ariadna Anunciacion-Llunell, Francesc Miró-Mur, Jaume Alijotas-Reig, and Josep Pardos-Gea
- Subjects
Proteomics ,Study groups ,business.industry ,Immunology ,Autoantibody ,Thrombosis ,Disease ,medicine.disease ,Bioinformatics ,Antiphospholipid Syndrome ,Antiphospholipid syndrome ,Immunology and Allergy ,Medicine ,Humans ,Aps diagnosis ,business ,Patient stratification ,Cellular proteins ,Biomarkers ,Biological Phenomena - Abstract
Identification of differentially expressed proteins in antiphospholipid syndrome (APS) is a developing area of research for unique profiles of this pathology. Advances in technologies of mass spectrometry brings improvements in proteomics and results in assessment of soluble or cellular proteins which could be candidates for clinical biomarkers of primary APS. The use of blood as a source of proteins ease the acquisition of samples for proteomics analyses and later for disease diagnosis. We performed a systematic review to explore the proteomics studies carried out in circulating released proteins (serum, plasma) or cellular proteins (monocytes and platelets) of APS patients. The study groups differentiate among clinical APS cases with the aim to translate molecular findings to disease stratification and to improve APS diagnosis and prognosis. These studies also include the unravelling of new autoantibodies in non-criteria APS or how post-translational protein modifications provides clues about the pathological mechanisms of antigen-autoantibody recognition. Herein, we identified 82 proteins that were dysregulated in APS across eleven studies. Enrichment analysis revealed its connection to cellular activation and degranulation that eventually leads to thrombosis as the main biological process highlighted by these studies. Validation of APS-relevant proteins by functional and mechanistic studies will be essential for patient stratification and the development of targeted therapies for every clinical subtype of APS.
- Published
- 2021
5. Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry∗
- Author
-
Josep Pardos-Gea, Elisa Llurba, Jaume Alijotas-Reig, Elmina Lefkou, Luca Marozio, Enrique Esteve-Valverde, Gerard Espinosa, Luis Sáez-Comet, Angela Tincani, Karoline Mayer-Pickel, Arsène Mekinian, Cecilia Nalli, Omar Latino, Tatiana Reshetnyak, Amelia Ruffatti, Sara De Carolis, Udry Sebastian, Anna Arnau, Vittorio Pengo, Cecilia Beatrice Chighizola, Cristina Belizna, Raquel Ferrer-Oliveras, Laura Trespidi, Valentina Canti, Patrizia Rovere-Querini, Sara Tabacco, Alijotas-Reig, J., Esteve-Valverde, E., Ferrer-Oliveras, R., Saez-Comet, L., Lefkou, E., Mekinian, A., Belizna, C., Ruffatti, A., Tincani, A., Pardos-Gea, J., Nalli, C., Marozio, L., Espinosa, G., De Carolis, S., Latino, O., Sebastian, U., Llurba, E., Trespidi, L., Chighizola, C., Pengo, V., Rovere-Querini, P., Canti, V., Mayer-Pickel, K., Reshetnyak, T., Tabacco, S., and Arnau, A.
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Hemorrhage ,Cesarean Section ,Female ,Heparin, Low-Molecular-Weight ,Humans ,Pregnancy ,Prospective Studies ,Registries ,Retrospective Studies ,Fibrinolytic Agents ,Pregnancy Complications ,Antiphospholipid syndrome ,medicine ,Caesarean section ,Prospective cohort study ,Aspirin ,Heparin ,Obstetrics ,business.industry ,Low-Molecular-Weight ,Retrospective cohort study ,medicine.disease ,Delivery mode ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,Anesthesiology and Pain Medicine ,Cohort ,business ,medicine.drug - Abstract
BACKGROUND The combination of low-dose aspirin (LDA) and low-molecular-weight heparin (LMWH) until the end of gestation are the currently the accepted standard of care for the treatment of antiphospholipid-related obstetric disorders. In refractory cases, hydroxychloroquine (HCQ) can be added to this standard of care. OBJECTIVE To evaluate the haemostatic safety of LDA and LMWH (medium to high prophylactic doses) during pregnancy and the puerperium in women with both full-blown obstetric antiphospholipid syndrome (OAPS) (Sydney criteria) and noncriteria - incomplete - OAPS. STUDY DESIGN Retrospective/prospective multicentre observational study. Obstetric background, laboratory categories, delivery mode, antithrombotic regimens and bleeding complications were compared. SETTING A total of 30 tertiary European hospitals. PATIENTS Mainly, Caucasian/Arian pregnant women were included. Other ethnicities were minimally present. Women were controlled throughout pregnancy and puerperium. MAIN OUTCOME MEASURES The primary end-point was to evaluate the number of major and minor haemorrhagic complications in this cohort of women. Neuraxial anaesthetic bleeding complications were particularly assessed. Secondly, we aimed to compare local/general bleeding events between groups. RESULTS We studied 1650 women, of whom 1000 fulfilled the Sydney criteria of the OAPS and 650 did not (noncriteria OAPS). Data on antithrombotic-related complications were available in 1075 cases (65.15%). Overall, 53 (4.93%) women had bleeding complications, with 34 being considered minor (3.16%) and 19 major (1.76%). Neither obstetric complications nor laboratory categories were bleeding-related. Assisted vaginal delivery and caesarean section were related to local haemorrhage. Heparin doses and platelet count were not associated with major bleeding. CONCLUSIONS LDA and medium to high prophylactic LMWH during pregnancy in women with full-blown OAPS/noncriteria OAPS are safe. A slight increase in bleeding risk was noted in instrumental deliveries. No women who underwent spinal or epidural anaesthesia suffered bleeding complications. No haemorrhage was observed in cases where HCQ was added to standard therapy.
- Published
- 2021
6. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review
- Author
-
Enrique Esteve-Valverde, Jaume Alijotas-Reig, Josep Pardos-Gea, Ariadna Anunciacion-Llunell, Cristina Belizna, Angela Quintana, Arsène Mekinian, Francesc Miró-Mur, and Albert Selva-O'Callaghan
- Subjects
0301 basic medicine ,SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2 ,PTE, Pulmonary thromboembolism ,Angiotensin-Converting Enzyme Inhibitors ,TGF-β, Transforming growth factor-beta ,Cytokine storm ,medicine.disease_cause ,Immunosuppressive ,Pathogenesis ,MERS-CoV, Middle East Respiratory Syndrome Coronavirus ,0302 clinical medicine ,Risk Factors ,HCQ, Hydroxychloroquine ,Immunology and Allergy ,CQ, Chloroquine ,IL, Interleukin ,NHC, National Health Council ,mTOR, Mammalian target of Rapamycin ,Coronavirus ,COVID-19, Coronavirus disease 2019 ,Acute respiratory distress syndrome ,RA, Rheumatoid arthritis ,aPL, Antiphospholipid antibodies ,Immunoglobulins, Intravenous ,APC, Antigen-presenting cells ,CDC, Centres for disease control ,PIC, Pulmonary intravascular coagulation ,Cytokines ,TLR, Toll-Like Receptor ,medicine.symptom ,Coronavirus Infections ,JAK, Janus-Kinase family of enzymes (JAK1, JAK2, JAK3, TYK2) ,medicine.drug ,CyA, Cyclosporine A ,TNF-α, Tumour necrosis factor-alpha ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Immunology ,Inflammation ,Antiviral Agents ,Article ,NK, natural killer cells ,WHO, World Health Organization ,IFNγ, Interferon gamma ,LMWH, Low-molecular weight heparin ,Immunomodulation ,Antimalarials ,Betacoronavirus ,03 medical and health sciences ,GCS, Glucocorticoids ,ACE-2, Angiotensin-converting enzyme-2 ,ADE, Antibody dependent enhancement ,medicine ,Humans ,TCZ, Tocilizumab ,Glucocorticoids ,Pandemics ,Janus Kinases ,TRAASVIR, Thrombotic Risk Associated with Antiphospholipid Syndrome after Viral infection ,030203 arthritis & rheumatology ,SARS-CoV-2 ,AD, Autoimmune diseases ,business.industry ,SLE, Systemic Lupus Erythematosus ,COVID-19 ,Anticoagulants ,Hydroxychloroquine ,medicine.disease ,Tregs, Regulatory T-cells ,HPS, Haemophagocytic syndrome ,Treatment ,Calcineurin ,030104 developmental biology ,ADRS, Acute distress respiratory syndrome ,MHC-II, Major histocompatibility type-II ,IVIG, Intravenous immunoglobulins ,CD, Cluster of differentiation or cluster of designation or classification determinant ,FDA, Food and Drugs Administration ,MDA5, Melanoma differentiation-associated gene 5 ,MAS, Macrophage activation syndrome ,NF-kβ, Nuclear Factor-Kβ ,TRALI, Transfusion-related acute lung injury ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business - Abstract
Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called “cytokine storm”. The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19., Higlights • Severe COVID-19 forms may be related to a hyperinflammatory syndrome. • Severe COVID-19 is associated with clot pathway hyperactivity and sometimes, with thromboses. • Immunosuppression may be a complementary therapy in COVID-19 patients. • Antimalarials, heparin, cytokine blockers, JAK-inhibitors, IVIG could be useful for treating severe COVID-19 patients. • In SARS-CoV-2 infections the effectiveness of the hyperimmune plasma remains uncertain.
- Published
- 2020
7. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study
- Author
-
C. Altisent, Josep Ordi-Ros, Miquel Vilardell-Tarrés, Josep Pardos-Gea, and Rafael Parra
- Subjects
medicine.medical_specialty ,Cyclophosphamide ,Combination therapy ,business.industry ,Encephalopathy ,Hematology ,General Medicine ,medicine.disease ,Gastroenterology ,Tacrolimus ,Surgery ,Calcineurin ,Internal medicine ,Medicine ,Rituximab ,business ,Prospective cohort study ,Survival rate ,Genetics (clinical) ,medicine.drug - Abstract
Acquired haemophilia A (AH) is defined as the presence of autoantibodies or inhibitors against factor VIII (FVIII) with a clinical bleeding onset that can be life-threatening. Immunosuppressant therapy must be initiated rapidly to eradicate the inhibitor. Current treatments based on steroids plus cyclophosphamide or rituximab are quite effective, but with significant side-effects. Based on previous described AH cases treated with cyclosporine, with a good side-effect profile, we aimed at assessing prospectively a first-line calcineurin inhibitor based immunosuppressive therapy. We included a total of 11 patients affected with AH. Once diagnosed, pulse steroids and calcineurin inhibitors were started. Time to achieve sustained response (SR), defined as testing negative for inhibitor and with stable FVIII level >50%, immunosuppressant side-effects, and relapse of AH were evaluated. Eight patients received cyclosporine and three patients received tacrolimus. SR was achieved in 10 of 11 patients (90.9%) in a median time of 3 weeks (range 2-8 weeks), and none of them relapsed during a median follow-up time of 14 months (range 4-120). One major side-effect appeared (posterior encephalopathy) that forced to discontinue cyclosporine. Overall 5-year survival rate was 54.5%, with a total of five patients dying during the follow-up (mortality rate of 45.5%). These five patients had achieved SR and died because of complications of basal morbidities and/or senescence, not related to AH (bleeding) or to immunosuppressant's (infection) side-effects. Combination therapy of calcineurin inhibitors and pulse steroids seems clinically effective as a first-line treatment of AH.
- Published
- 2012
8. Beta2-glycoprotein I gene polymorphisms Val247Leu and Trp316Ser in Spanish patients with primary antiphospholipid syndrome
- Author
-
Josep Ordi-Ros, Eva Balada, Josep Pardos-Gea, A. Pedrosa, Miquel Vilardell-Tarrés, Jesús Castro-Marrero, and Josefina Cortés-Hernández
- Subjects
Adult ,Male ,Genotype ,Immunology ,Polymorphism, Single Nucleotide ,White People ,Pathogenesis ,Gene Frequency ,Rheumatology ,Humans ,Immunology and Allergy ,Medicine ,Genetic Predisposition to Disease ,Allele ,Gene ,Alleles ,Genetics ,Beta2-Glycoprotein I ,biology ,business.industry ,Autoantibody ,Middle Aged ,Antiphospholipid Syndrome ,Primary antiphospholipid syndrome ,Spain ,beta 2-Glycoprotein I ,Antibodies, Antiphospholipid ,biology.protein ,Female ,Antibody ,business - Abstract
The significance of beta2-glycoprotein I (β2GPI) polymorphisms in the production of anti-β2GPI and other antiphospholipid autoantibodies (aPL) and in the pathogenesis of primary antiphospholipid syndrome (PAPS) is not well understood. We performed a study comparing the distribution of polymorphisms at codons 247 (Val247Leu) and 316 (Trp316Ser) of the β2GPI gene in a Caucasian Spanish population of PAPS patients and healthy controls, and then making correlations with the development of anti-β2GPI antibodies and other aPL and associated clinical manifestations. A total of 57 PAPS patients and 100 control subjects were included. In the analysis of Val247Leu polymorphism, alleles (V and L) and genotypes (V/V, V/L, L/L) were similarly distributed in PAPS patients and controls (P = 0.66 and P = 0.22, respectively). Regarding Trp316Ser polymorphism, we found a higher percentage of patients with respect to controls expressing S allele (11.4 vs. 5%, P = 0.02) and T/S genotype (22.8 vs. 10%, P = 0.02). However, when we compared T/T and T/S genotypes in PAPS patients, we found no differences regarding generation of anti-β2GPI, other aPL and clinical manifestations favoring any genotype. Our findings suggest that among Spanish Caucasians, polymorphisms at codon 247 (Val247Leu) do not seem to influence PAPS pathogenesis. On the contrary, polymorphisms at codon 316 (Trp316Ser), by means of an increased S allele and T/S genotype presence in Spanish Caucasian patients, might play a role in the pathogenic development of PAPS, although mechanism would not involve an increased production of anti-β2GPI and other aPL.
- Published
- 2011
9. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients
- Author
-
Josep Pardos-Gea, Eva Balada, Josep Ordi-Ros, Miguel Vilardell, Josefina Cortés-Hernández, Arturo Evangelista, and Gustavo Avegliano
- Subjects
Adult ,Male ,medicine.medical_specialty ,Livedo ,Time Factors ,Heart Valve Diseases ,Rheumatology ,Valvular disease ,Antiphospholipid syndrome ,Internal medicine ,medicine ,Humans ,Prospective Studies ,cardiovascular diseases ,Prospective cohort study ,Ultrasonography ,business.industry ,Follow up studies ,Antiphospholipid Syndrome ,Prognosis ,medicine.disease ,Migraine ,cardiovascular system ,Cardiology ,Female ,Transthoracic echocardiogram ,business ,Follow-Up Studies - Abstract
The evolution of valvular disease in antiphospholipid syndrome (APS) is barely known. In order to evaluate whether the presence or absence of valvular disease at the time of diagnosis of APS, assessed by an initial echocardiogram, predicts its subsequent evolution, we performed a prospective cohort study. We included 53 patients with APS. An initial transthoracic echocardiogram was performed on patients at the time of diagnosis of APS. Serial echocardiograms were conducted along a 12-year follow-up. Final echocardiograms were used for comparative purposes. We started with 29 patients (54%) with and 24 (45%) without valvulopathy at initial echo. At the final echocardiogram, 27 of 29 patients with initial valvulopathy continued to have valvular disease (a 93% observed likelihood), and 22 of 24 patients without initial valvulopathy demonstrated an absence of valvular disease (a 91% observed likelihood). Patients with valvulopathy in comparison with those without presented more arterial thrombotic events (69% vs. 20%, P < 0.001), atherosclerotic risk factors (62% vs. 29%, P = 0.01), livedo (48% vs. 16%, P = 0.01) and migraine (41% vs. 12%, P = 0.02). We have identified two subtypes of APS patients with and without valvulopathy by defining differential clinical features and with little crossover in valvular involvement over a long follow-up period, giving a high prognostic value to the initial echocardiographic assessment. Lupus (2010) 19, 575—582.
- Published
- 2010
10. Chronic intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus
- Author
-
Miguel Vilardell, J Perez-Lopez, A. Selva, Josep Ordi-Ros, Josep Pardos-Gea, and Eva Balada
- Subjects
Adult ,Intestinal pseudo-obstruction ,medicine.medical_specialty ,Paralytic ileus ,Hydronephrosis ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Smooth muscle ,immune system diseases ,Internal medicine ,Female patient ,medicine ,Humans ,Lupus Erythematosus, Systemic ,Biliary Tract ,skin and connective tissue diseases ,030203 arthritis & rheumatology ,Systemic lupus erythematosus ,Bile duct ,business.industry ,Intestinal Pseudo-Obstruction ,Glomerulonephritis ,medicine.disease ,Lupus Nephritis ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,Biliary tract ,Female ,business ,Dilatation, Pathologic - Abstract
We present the case of a 57-year old female patient diagnosed with systemic lupus erythematosus (SLE) along with glomerulonephritis and chronic intestinal pseudo-obstruction (CIPO). Dilatation of bile and pancreatic ducts not associated with malignant or litiasic obstruction is reported. The combination of bile duct associated with CIPO in a patient with lupus has not been previously reported in the literature and it probably suggests a smooth muscle dysmotility.
- Published
- 2005
11. Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis
- Author
-
Carmen-Pilar Simeón-Aznar, Eva Balada, Josep Pardos-Gea, V. Fonollosa-Pla, Maria Rosa-Leyva, Albert Selva-O'Callaghan, Miquel Vilardell-Tarrés, and Josep Ordi-Ros
- Subjects
Adult ,medicine.medical_specialty ,Receptor, Platelet-Derived Growth Factor alpha ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Sensitivity and Specificity ,General Biochemistry, Genetics and Molecular Biology ,Scleroderma ,Epitope ,Serology ,Affinity maturation ,Rheumatology ,Immunopathology ,Internal medicine ,Immunology and Allergy ,Medicine ,Humans ,Aged ,Autoantibodies ,Aged, 80 and over ,Scleroderma, Systemic ,biology ,business.industry ,Autoantibody ,Middle Aged ,medicine.disease ,Endocrinology ,Immunoglobulin class switching ,biology.protein ,Electrophoresis, Polyacrylamide Gel ,Female ,Antibody ,business ,Biomarkers - Abstract
Objective: To evaluate the presence of anti-PDGFR-α antibodies by immunological methods in patients with systemic sclerosis (SSc). Methods: Fifty-eight women diagnosed with SSc and 36 healthy women controls were included. IgG anti-PDGFR-α were measured by ELISA and immunoblot. Associations with clinical and immunological findings were also studied. Results: Non-statistically significant differences were detected between SSc patients and controls: median value: 0.287 (range: 0-2.06) vs. median value: 0.226 (range: 0-2.94), respectively (p = 0.583). None correlation between the presence of anti-PDGFR-α antibodies and clinical and serologic features was observed. Sera from SSc patients and healthy people who showed high titers of anti-PDGFR-α antibodies by ELISA recognized the same band corresponding to PDGFR-α by immunoblot. Conclusion: Although anti-PDGFR-α antibodies seem to be disease-specific when determined by bioactivity assays, these antibodies are also detected in normal subjects when immunological methods are performed. Thus, our study leads to the hypothesis that anti-PDGFR-α antibodies may arise from natural autoantibodies. It is possible that SSc-autoantibodies recognize a different epitope on the PDGFR-α molecule which triggers its stimulatory effect when analyzed by functional assays. Alternatively, naturally occurring autoantibodies would even become pathogenic after suffering some kind of affinity maturation and class switching in genetically susceptible individuals.
- Published
- 2008
12. Miositis por cuerpos de inclusión y síndrome de Sjögren primario
- Author
-
Josep Pardos Gea, Josep M. Grau Junyent, Albert Selva O'Callaghan, and Jordi Sans Valeta
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,General Medicine ,business - Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.